@ARTICLE{
author={Brodowicz Thomas,Ciuleanu Tudor E,Radosavljevic Davorin Z,Shacham-Shmueli Einat,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank M,Purkalne Gunta,Messinger D,Zielinski Christoph},
year={2013},
title={FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study},
journal={ANNALS OF ONCOLOGY},
volume={24},
number={7},
pages={1769-1777},
document_type={Article},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shmueli E,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank M,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={29},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shmueli E,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank Magdolna,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={29},
number={4},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shacham-Shmueli Einat,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Kahan Zsuzsanna,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab Weekly (Q1W) Versus Every Two Weeks (Q2W) Plus Folfox4 as First-line Therapy in Patients (PTS) with Kras Wild-Type (WT) Metastatic Colorectal Cancer (MCRC)},
journal={ANNALS OF ONCOLOGY},
volume={22},
number={},
pages={v22-v22},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Elsakov Pavel,Foretova Lenka,Goetz Petr,de Groot Johannes WB,van der Graaf Winette TA,Guler Gulnur,Huebner Kay,Haites Neva E,Hamann Ute,Ho Judy,Imyanitov Evgeny N,Irmejs Arvids,Purkalne Gunta,Bitina Marianna,Gardovskis Andris,Gardovskis Janis,Kirova Youlia M,Fourquet Alain,Pierga Jean-Yves,Stoppa-Lyonnet Dominique,Larizza Lidia,Lips Cornelis JM,Loman Niklas,Borg Ake,Moller Pal,Olsson Hakan,Park Jae-Gahb,Radulovic Sinisa S,Brankovic-Magic Mirjana V,Rajkumar Thangarajan,Razis Evangelia,Yannoukakos Drakoulis,Schmitt Fernando,Schmutzler Rita,Simmonds Peter D,Eccles Diana,Smeltzer Jacob,Silberstein Peter T,Lynch Henry,Weber Walter,Willemse Pax HB,Sijmons Rolf H,Wysocki Piotr J,Zajac Vladimir,Shu Zheng},
year={2007},
title={Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers},
journal={HEREDITY CANCER IN CLINICAL PRACTICE},
volume={5},
number={3},
pages={119-143},
document_type={Editorial Material},
}